<DOC>
	<DOCNO>NCT01718288</DOCNO>
	<brief_summary>Evaluate possibility optimization therapy prostanoids ( iloprost ) , patient Fontaine 's stage IIb severe chronic ischemia , patient eligible surgery patient possible medical therapy</brief_summary>
	<brief_title>Optimization Treatment Patients With Severe Peripheral Ischemia ( Fontaine Stage IIb )</brief_title>
	<detailed_description>The management patient peripheral arterial disease ( PAD ) stage IIb pain-free walking distance ( PFWD ) less 100 meter major clinical problem , view significant cooling quality life evolution often severe characterizes clinical course patient . Revascularization Surgery treatment choice , half patient severe PAD IIb eligible surgery endovascular treatment . The usefulness use vasodilator hemorheological controversial , medical treatment patient therefore heterogeneous understand various pharmacologic option ( correction risk factor , prevention cardiovascular event , improvement claudication ) , rehabilitative program . Iloprost , synthetic analogue prostacyclin , effective treatment patient chronic critical ischemia , pharmacological profile ( effective vasodilator , anti-platelet , leukocyte activation ) particularly suitable modulate multiple component pathogenesis peripheral arterial disease . Specifically , treatment patient PAD IIb severe , current state available retrospective study compare use iloprost vasodilator . Aim study FADOI-2bPILOT evaluate prospectively observation period 13 month , get benefit pain-free walking distance clinical outcome `` anticipated '' additional use iloprost , patient severe IIb stage PAD treat accord current `` best medical practice '' .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Vasodilator Agents</mesh_term>
	<criteria>age &gt; 18 year ; painfree walk distance ( PFWD ) &lt; 100 meter two occasion 10 day apart , &lt; 25 % difference ; ankle blood pressure ( BP ) &lt; 70 mmHg ; big toe BP &lt; 30 mmHg ( case diabetic patient ) . pain rest , trophic ulcer gangrene ( critical limb ischemia ) , unable cooperate , one follow condition ( contraindication precaution use iloprost ) present : myocardial infarction stroke previous 6 month ; congestive heart failure NYHA class &gt; II ; unstable angina ; uncontrolled severe arterial hypertension ( systolic BP &gt; 180 mmHg diastolic BP &gt; 110 mmHg ) hypotension ( systolic BP &lt; 90 mmHg ) ; hyperkinetic ventricular arrhythmia ; acute pulmonary edema pulmonary congestion ; bleed diathesis ; platelet count &lt; 80,000 &gt; 500,000/mm3 ; renal failure require dialysis ; liver cirrhosis ; pregnancy breast feeding ; history allergy , hypersensitivity intolerance iloprost prostanoids .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>PAD ; iloprost ; walk distance ; cardiovascular event</keyword>
</DOC>